

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 67465

Title: The magnetic resonance imaging-radiomics evaluation of response to

chemotherapy for synchronous liver metastasis of colorectal cancer

Reviewer's code: 03827272 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Canada

Author's Country/Territory: China

Manuscript submission date: 2021-04-25

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-25 23:37

Reviewer performed review: 2021-04-26 03:01

Review time: 3 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No
Statements	Connects of interest. [] 165 [1] 140



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Absrtact ,background: Consider changing the sentence for: Synchronous liver metastasis (SLM) is a indicator of poor prognostic for colorectal cancer (CRC). Nearly 50% of colorectal cancer (CRC) patients develop hepatic metastasis and 15-25% of these patients have synchronous liver metastases (SLM). Same sentence to be changed in the Core tip The final version of the manuscript needs to be re-reviewed by a linguist. There are still numerous grammatical errors. Methods: If I understand correctly, the gold standard used to determine whether a patient had disease response or not were the RECIST criterias. RECIST criterias are not perfect in Colorectal cancer, especially with mucinous tumours where the size of the lesions rarely vary significantly while there can still be a pathological evidence of treatment effect. Nothing is said in this article about histopathology but adding histopathological evidence of chemotherapy treatment effect in deciding if a patient belongs to the DR group or non-DR would be more thorough and complimentary to the results of the radiomics analysis. Table 1. Please re-calculate CA19-9 difference between non-DR and DR and adjust results and discussion. When I calculate it myself, there aren't any significant difference between the two groups